The in vitro susceptibilities to various antimicrobial agents of 100 strains of a-lactamase-producing Haemophilus ducreyi recently isolated from patients in New Orleans, La., were determined by an agar dilution method. All strains were highly susceptible to ceftizoxime, ceftriaxone, ceftazidime, azithromycin, erythromycin, ciprofloxacin, and sparfloxacin. 13-Lactam-13-lactamase inhibitor combinations were less active, but all strains were susceptible to them. Doxycycline exhibited the poorest activity, and the rate of resistance to doxycycline varied depending on the time after inoculation that the MIC was determined.
Haemophilus ducreyi is the etiologic agent of chancroid, an important cause of genital ulcers worldwide. The disease is characterized by the development of single or multiple ulcerative lesions on the genitalia and may cause extensive destruction to the surrounding tissue. The infectious process often extends to the inguinal lymph nodes, resulting in a painful lymphadenitis, which may progress to bubo formation with suppuration. The latter may occur despite effective antimicrobial therapy in some cases. The major public health concern over chancroid is that studies in Africa have shown that the disease is a significant cofactor in the transmission of the human immunodeficiency virus (14) .
Early in the antibiotic era, H. ducreyi was susceptible to almost all available drugs. However, increasing resistance has been documented among isolates from around the world. Most isolates are now 1-lactamase producers and are also resistant to tetracycline (11) . Increasing resistance to the sulfonamides, including trimethoprim-sulfamethoxazole, has been noted as well (12) . Therefore, continued surveillance for the development of new resistance patterns among H. ducreyi strains is important. In the present study we compared the in vitro activities of several parenteral and oral antimicrobial agents against strains of H. ducreyi recently isolated from patients with chancroid in New Orleans, La., where a resurgence of this disease was first observed late in 1988.
One hundred clinical isolates of H. ducreyi were collected from the genital ulcers of patients attending a local sexually transmitted disease clinic. Swabs from the lesions were plated onto (i) heart infusion agar (Difco) supplemented with 5% defibrinated rabbit blood-5% fetal bovine serum-1% IsoVitaleX-3 p,g of vancomycin per ml and (ii) GC II agar (BBL) supplemented with 1% bovine hemoglobin-5% fetal bovine serum-1% IsoVitaleX-3 ,ug of vancomycin per ml. Culture plates were streaked for organism isolation, incubated at 33°C in 6% CO2 in a humidified chamber, and read daily for 7 days for the growth of typical waxy, yellow colonies. Typical colonies were subcultured onto chocolate II agar (BBL) for further identification. Identification Table 1 compares the in vitro activities of the various antimicrobial agents against the H. ducreyi strains. All three of the expanded-spectrum cephalosporins were highly active against these strains. Bower et al. (4) have shown similar in vitro results for both ceftriaxone and ceftazidime and excellent clinical efficacy of single-dose ceftriaxone administered intramuscularly in the treatment of chancroid. Our results with ceftizoxime suggest that this agent could be as effective clinically as ceftriaxone on the basis of its in vitro activity.
All of the test isolates were ,3-lactamase producers. ,3-Lactamase-producing strains of H. ducreyi have been shown to be resistant to penicillin and ampicillin (2) . Although not as active as the expanded-spectrum cephalosporins, the 3-lactam-,3-lactamase inhibitor combinations showed good activity. All combinations had comparable activities, and no resistant strains were detected. Other investigators (7, 10) have reported synergistic activity between amoxicillin and clavulanate against ,B-lactamase-producing strains of H. ducreyi.
For the macrolides, the test strains were highly susceptible to both azithromycin and erythromycin. Slaney et al. (13) have previously reported that azithromycin has good activity against H. ducreyi strains originating from various parts of the world. Other investigators (2) Doxycycline was the only antimicrobial agent tested that showed an appreciable shift in the resistance rates between the readings at 24 and 48 h by using a susceptibility cutoff value of 54 ,ug/ml. At 24 h, the MICs for 79 strains were c4 ,ug/ml, while the MICs for 21 strains were 28 ,ug/ml. At 48 h, the MICs for 17 strains were c4 jig/ml and the MICs for 83 strains were .8 p,g/ml. Bilgeri et al. (2) reported that for some H. ducreyi strains, doxycycline MICs were elevated at 24 h; however, they did not perform a reading at 48 h.
Clinical resistance to tetracycline has been recognized since the early 1970s (1, 8) . The reading of MICs of doxycycline at 48 h appears to be more predictive of clinical outcome. Modest upward shifts in the MIC profiles for several of the other drugs tested in the present study were noted at 48 h, but in all of these cases the MICs were below the breakpoint, so there appeared to be no benefit in delaying the MIC reading until 48 h. The present study showed that many orally and parenterally administered antimicrobial agents possess in vitro activity against ,3-lactamase-producing H. ducreyi strains isolated from November 1988 through November 1991 in New Orleans. Overall, the isolates were highly susceptible to expanded-spectrum cephalosporins, fluoroquinolones, and macrolides. ,B-Lactam-p-lactamase inhibitor combinations also showed good activity, while doxycycline was virtually inactive. The current recommendations for treating chancroid in the United States, as summarized in CDC guidelines in 1989 (5), include a singledose regimen of ceftriaxone and multiple-dose regimens of erythromycin, ciprofloxacin, and ampicillin-clavulanic acid.
Thus, our in vitro testing appears to be a valid predictor of in vivo efficacy with these antimicrobial agents.
